Elkattawy Hany A, Alsemeh Amira Ebrahim, Ali Lashin Saad, Ahmed Mona Mostafa, Eltaweel Asmaa Monir, Shaikh Farha M, Behiry Ahmed, Hassan Ahmed El-Sayed, Sabir Deema Kamal, Elsherbini Dalia Mahmoud Abdelmonem, Ali Sahar K, Zakari Madaniah Omar, Mojaddidi Moaz Abdullah, Ali Ehab Kamal, Elbastawisy Yasser M, Hadhoud Shimaa
Department of Basic Medical Sciences, College of Medicine, AlMaarefa University, Diriyah 13713, Saudi Arabia.
Human Anatomy and Embryology Department, Faculty of Medicine, Zagazig University, P.O. Box 44519, Zagazig, Egypt.
Tissue Cell. 2025 Apr;93:102689. doi: 10.1016/j.tice.2024.102689. Epub 2024 Dec 15.
Endocrine multisystem defect polycystic ovary syndrome (PCOS) causes hyperandrogenism and infertility. Half of PCOS women have (non-alcoholic fatty liver disease) NAFLD, which increases metabolic disease risk. We tested decorin's effect on NAFLD and related processes in PCOS. NAFLD+PCOS, PCOS+decorin, and control rats were studied. Decorin was evaluated on NAFLD/PCOS rats. Test group rats received HF for eight weeks to generate NAFLD. The rats got 1 mg/kg letrozole orally daily for 21 days to diagnosis PCOS. Afterward, rats got injectable decorin for 14 days. Body weight, liver weight, liver coefficient Abdominal Circumference (AC) and body mass index (BMI) were determined. Blood triglycerides (TG), total cholesterol, LDL-c, AST, and glucose were measured. The insulin, testosterone, estrogen, LH, and FSH were measured by ELISA. GPx, SOD, MDA, TNF-, and Caspase-3 liver immunohistochemistry were evaluated. NAFLD liver tissues in PCOS models showed biochemical and histological alterations. NAFLD+PCOS raised BMI, AC, liver weight, and coefficient. Blood glucose, insulin resistance, TG, ALT, and AST increased. Lipid abnormalities (TG, cholesterol, LDL-c, and HDL-c), oxidative stress markers (MDA, SOD, and GPx), and liver dysfunction were found. Low serum E2 and high T supported PCO. Decorin reduced model rat BMI, liver weight, coefficient, insulin resistance, TG, ALT, and AST. It reduced liver inflammation, improved liver extract lipids, and normalized MDA, SOD, and GPx. In the model group, decorin lowered serum T, E2, LH, caspase 3, and TNF-alpha. Decorating improved NAFLD/PCOS group liver histology and function. Decorin reduces hepatosteatosis by reducing liver inflammation, oxidative stress, and dyslipidemia.
内分泌多系统缺陷多囊卵巢综合征（PCOS）会导致高雄激素血症和不孕。半数PCOS女性患有非酒精性脂肪性肝病（NAFLD），这会增加代谢性疾病风险。我们测试了核心蛋白聚糖对PCOS中NAFLD及相关过程的影响。对NAFLD+PCOS、PCOS+核心蛋白聚糖和对照大鼠进行了研究。在NAFLD/PCOS大鼠身上评估了核心蛋白聚糖。试验组大鼠接受8周的高脂饮食以诱发NAFLD。大鼠每天口服1mg/kg来曲唑，持续21天以诊断PCOS。之后，大鼠接受注射用核心蛋白聚糖治疗14天。测定体重、肝脏重量、肝脏系数、腹围（AC）和体重指数（BMI）。测量血液甘油三酯（TG）、总胆固醇、低密度脂蛋白胆固醇、天冬氨酸转氨酶（AST）和血糖水平。通过酶联免疫吸附测定法（ELISA）测量胰岛素、睾酮、雌激素、促黄体生成素（LH）和促卵泡生成素（FSH）。评估肝脏中谷胱甘肽过氧化物酶（GPx）、超氧化物歧化酶（SOD）、丙二醛（MDA）、肿瘤坏死因子-α（TNF-）和半胱天冬酶-3（Caspase-3）的免疫组织化学情况。PCOS模型中的NAFLD肝脏组织显示出生化和组织学改变。NAFLD+PCOS组的BMI、AC、肝脏重量和系数升高。血糖、胰岛素抵抗、TG、谷丙转氨酶（ALT）和AST升高。发现存在脂质异常（TG、胆固醇、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇）、氧化应激标志物（MDA、SOD和GPx）以及肝功能障碍。低血清雌二醇（E2）和高睾酮（T）支持PCOS诊断。核心蛋白聚糖降低了模型大鼠的BMI、肝脏重量、系数、胰岛素抵抗、TG、ALT和AST。它减轻了肝脏炎症，改善了肝脏脂质提取，并使MDA、SOD和GPx恢复正常。在模型组中，核心蛋白聚糖降低了血清T、E2、LH、半胱天冬酶3和肿瘤坏死因子-α水平。核心蛋白聚糖改善了NAFLD/PCOS组的肝脏组织学和功能。核心蛋白聚糖通过减轻肝脏炎症、氧化应激和血脂异常来减少肝脂肪变性。
